GHK-Cu Side Effects: What the Topical Trials Report and What Injectable Use Is Missing

"GHK-Cu side effects" gets searched around 1,900 times a month, and the honest answer depends entirely on which GHK-Cu a reader means. As our evidence review covers in full, GHK-Cu genuinely differs from BPC-157, TB-500, KPV, and MOTS-c in one specific way: it has real, controlled human trials behind it — going back more than three decades. It differs in another way too, in the opposite direction: every one of those human trials tested the topical, cosmetic form. The injectable, systemic GHK-Cu sold in a compounded, reconstituted vial — the product this site's calculator exists for — has zero published human trials of any kind, safety included. This article keeps those two routes separate throughout, the same discipline our evidence review applies to efficacy.

What the topical human trials report about safety

GHK-Cu's entire controlled-trial record, topical or otherwise, is two small human RCTs plus one animal trial — read here specifically for what each says about safety rather than the efficacy result our evidence review already covers:

• •The 1992 venous-ulcer trial. This trial predates the kind of structured, itemized adverse-event reporting a modern RCT publishes, and its own available text does not report a distinct safety tally for the GHK-Cu cream arm — a reporting-era limitation this article states directly rather than treating an absent adverse-event section as a clean safety result¹.
• •The 2006 laser-resurfacing trial. This more recent, smaller trial (13 patients) reports "no statistically significant differences between groups" on its objective measures, and patient satisfaction was significantly higher in the GHK-Cu group² — a real, reported patient-experience finding. Its own abstract does not separately report an adverse-event finding for either study arm.

Neither trial reports a specific safety signal, positive or negative, for topical GHK-Cu — the honest read is that these two small, decades-old studies weren't built or reported in a way that answers the safety question with much precision either way, independent of what they found on efficacy.

What the injectable/systemic evidence reports about safety — which is to say, almost nothing human

This is where the gap widens sharply. No human trial — topical or otherwise — has tested injected or systemically dosed GHK-Cu. What exists instead is a small set of animal studies, read here specifically for safety-adjacent findings:

• •Rat ACL reconstruction, 2015. The one study that actually injected GHK-Cu for the joint/tendon-repair use case it's often sold for: 72 rats received weekly intra-articular injections of GHK-Cu at 0.3 or 3 mg/mL, starting the second week after surgery, for 4 weeks³. No adverse finding is reported in the study's own results. What is worth reading as a safety-adjacent, not just an efficacy, detail: the measured benefit (reduced knee laxity, increased graft stiffness) had faded by 12 weeks — six weeks after the injections stopped — meaning whatever this study captured about GHK-Cu in the joint didn't persist once dosing ended, in either direction.
• •Mouse lung-disease models, 2020 and 2022. Two independent groups injected GHK-Cu intraperitoneally into mice with induced pulmonary fibrosis and emphysema, respectively, and both reported reduced inflammatory markers versus untreated disease — no adverse finding reported in either paper, though neither was a dedicated toxicology study.
• •Aged-mice cognitive study, 2026 — an unreviewed preprint. This study compared intraperitoneal against intranasal GHK-Cu dosing in aged mice, and — flagged here again because it wasn't peer-reviewed at time of posting — found the injectable route produced only a transient, male-limited benefit compared to a more consistent effect from the intranasal route. Not a safety finding either way, but a direct data point that the injectable route was the less effective one tested in this specific, unreviewed study.

No published human safety data exists for injected or systemically dosed GHK-Cu at any dose, in any study, for any duration. A live PubMed search for GHK-Cu combined with toxicity, adverse-event, and safety terms, re-run for this article, located no dedicated human safety study of the injectable route — the same zero-result finding our evidence review already reports for injectable efficacy trials extends fully to the safety question.

The regulatory record — a full step behind its own peptide-market neighbors

Injectable GHK-Cu's compounding-safety review is genuinely less advanced than BPC-157's, TB-500's, KPV's, or MOTS-c's — all four of which have already had their FDA Pharmacy Compounding Advisory Committee (PCAC) hearing and vote. Injectable GHK-Cu was placed in FDA's interim 503A Category 2 (significant safety risk) bulk-substances list in 2023, alongside those four, and removed from Category 2 on the same date, April 15, 2026, via nominator withdrawal — a procedural change, not a safety reversal⁴. But at the July 23-24, 2026 PCAC meeting where BPC-157, TB-500, KPV, and MOTS-c were all formally reviewed, injectable GHK-Cu was not among the seven substances discussed. FDA has instead said it will review injectable GHK-Cu at a separate meeting scheduled for before the end of February 2027, alongside four other peptides. As of this review, that meeting has not happened — meaning injectable GHK-Cu currently sits in an earlier, less-reviewed regulatory position than every other peptide in this site's non-board dosage/side-effects coverage.

Contamination and manufacturing-quality risk is a separate category no efficacy or safety study — topical or injectable — can speak to. As with every unapproved compounded peptide this site reviews, nothing above tells a reader what's actually in a specific vial from an unregulated seller.

What this means if you're weighing injectable GHK-Cu specifically

Put the two evidence records side by side and the picture is genuinely more nuanced than either "GHK-Cu is well-studied" or "GHK-Cu has no human data" — both are true, for different routes. Topical GHK-Cu has real, if old and reporting-limited, human trial data with no clear adverse signal reported either way. Injectable, systemic GHK-Cu — the form a compounded, reconstituted vial actually is — has zero published human data of any kind, safety included, and a regulatory review timeline running behind its own market neighbors. Nothing about a face cream's safety profile transfers to what an intramuscular or subcutaneous dose does systemically, and this article does not borrow one route's data to answer a question about the other. For a reader who has decided to buy the compounded injectable form despite this gap, our GHK-Cu provider comparison reads pharmacy sourcing and price directly off each seller's own site. For the vial-to-syringe arithmetic on a dose you already have from elsewhere, our GHK-Cu reconstitution calculator does that math without validating the number itself. For the full evidence picture on both routes, see our GHK-Cu evidence review; for the same non-recommendation approach applied to a peptide with no human trial data at either route, see our TB-500 dosage and side-effects review.